Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVRL1 | P37023 | 4/20 | 0.40 |
| ▸ | BRAF | P15056 | 4/20 | 0.40 |
| ▸ | TYK2 | P29597 | 9/20 | 0.39 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29304996 | 0.89 | ACVRL1 (0.44) | ACVRL1BRAFTYK2PIK3C3JAK2 | |
| SCHEMBL24738254 | 0.87 | ACVRL1 (0.44) | ACVRL1BRAFTYK2PIK3C3JAK2 | |
| SCHEMBL30997793 | 0.87 | KLKB1 (0.35) | — | |
| SCHEMBL29879134 | 0.86 | TYK2 (0.36) | BRAFTYK2 | |
| SCHEMBL24738252 | 0.86 | TYK2 (0.36) | BRAFTYK2 | |
| SCHEMBL24739118 | 0.80 | KLKB1 (0.37) | BRAFTYK2 | |
| SCHEMBL29880206 | 0.80 | KLKB1 (0.37) | BRAFTYK2 | |
| SCHEMBL29302908 | 0.80 | SYK (0.38) | TYK2JAK2JAK1JAK3 | |
| SCHEMBL24737728 | 0.79 | ACVRL1 (0.48) | ACVRL1BRAFTYK2PIK3C3JAK2 | |
| SCHEMBL24737786 | 0.78 | TYK2 (0.37) | BRAFTYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022197758-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |